A Phase III Clinical Trial of Buserelin versus Danazol in the Treatment of Endometriosis
This phase III trial investigated whether buserelin, a GnRH agonist causing hypoestrogenism, was superior to danazol for treating endometriosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Full text
2,280 characters
· extracted from
oa-doi-fallback
· 3 sections
· click to expand
Abstract
References
Keywords
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
References (5)
- Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens. via openalex
- W170259557 via openalex
- W1997894565 via openalex
- W2408619637 via openalex
- W2477008945 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00